Our Leadership


Robert Mashal

Robert Mashal

Joined Sanofi Genzyme: 2016

Robert Mashal is responsible for developing the overall strategy for the oncology and I&I (immunology and inflammation) franchises in collaboration with the leadership in research, development, and the GBU.

Prior experience

  • CEO, NKT Therapeutics
  • CEO, Alinea Pharmaceuticals
  • Partner, Boston Millennia Partners (BOD member Glycofi, Cardiomems, Novalar, Sapphire, CoApt Systems)
  • Program Executive, Vertex Pharmaceuticals
  • Consultant, McKinsey & Co.

Education

  • Johns Hopkins University
  • Johns Hopkins University, Economics/Natural Sciences